Patents by Inventor Li-Zhen Pan

Li-Zhen Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
    Publication number: 20030012781
    Abstract: The present invention is directed to antibodies which bind human gp39, are antagonistic of the CD40/CD40L interaction, but are non-agonistic of T-cell activation. The present invention is further directed to the use of these antibodies as therapeutic agents. These antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.
    Type: Application
    Filed: June 6, 2001
    Publication date: January 16, 2003
    Inventors: Anderson Darrell, Li-Zhen Pan, Nabil Hanna, William H. Rastetter, William S. Kloetzer
  • Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
    Patent number: 5955364
    Abstract: Novel human monoclonal antibodies, and their corresponding nucleic acid sequences having high affinity for the human RSV-F protein are provided.
    Type: Grant
    Filed: April 18, 1996
    Date of Patent: September 21, 1999
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Peter Brams, Soulaima Salim Chamat, Li-Zhen Pan, Edward E. Walsh, Cheryl Janne Heard, Roland Anthony Newman
  • Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
    Patent number: 5939068
    Abstract: A method of detecting RSV (Respiratory Syncytial Virus) in an analyte using high affinity human monoclonal antibodies is provided.
    Type: Grant
    Filed: April 18, 1996
    Date of Patent: August 17, 1999
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Peter Brams, Soulaima Salim Chamat, Li-Zhen Pan, Edward E. Walsh, Cheryl Janne Heard, Roland Anthony Newman
  • Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
    Patent number: 5866125
    Abstract: A method of obtaining high affinity human monoclonal antibodies having a Kd of .ltoreq.2.times.10.sup.-9 molar in SCID mice is provided.
    Type: Grant
    Filed: April 18, 1996
    Date of Patent: February 2, 1999
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Peter Brams, Soulaima Salim Chamat, Li-Zhen Pan, Edward E. Walsh, Cheryl Janne Heard, Roland Anthony Newman
  • Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
    Patent number: 5840298
    Abstract: A method of treating or preventing RSV infection by the administration of high affinity human monoclonal antibodies having a Kd of about 2.times.10.sup.-9 to 10.sup.-10 molar is provided.
    Type: Grant
    Filed: April 18, 1996
    Date of Patent: November 24, 1998
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Peter Brams, Soulaima Salim Chamat, Li-Zhen Pan, Edward E. Walsh, Cheryl Janne Heard, Roland Anthony Newman
  • Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
    Patent number: 5811524
    Abstract: A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein about 2.times.10.sup.-9 to 10.sup.-10 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 22, 1998
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Peter Brams, Soulaima Salim Chamat, Li-Zhen Pan, Edward E. Walsh, Cheryl Janne Heard, Roland Anthony Newman